Embed Size (px)
Citation preview
CSE:IN | OTCQB:IMLFF | www.inmedpharma.com
INMED PHARMACEUTICALS is a clinical stage biopharmaceutical company that specializes in
developing cannabis based therapies through the Research and Development into the extensive
pharmacology of cannabinoids coupled with innovative drug delivery systems.
Our Proprietary Platform Technology, Product Pipeline and accelerated Drug Discovery &
Development pathway are the fundamental value drivers of the Company.
Our therapy development process is based on two interrelated areas of R & D:
1 Drug Discovery and
Development 2 Nanoparticle Based Drug
Delivery System
The Company is utilizing its Intelligent Cannabinoid Drug
Design Platform “IDP” to identify new bioactive compounds in
cannabis & non cannabis plants that interact with certain genes
responsible for specific diseases. The “IDP” is an in silico tools to
offset & reduce the major challenges of drug development like:
Development time, Development cost and Risk of Attrition and
thus accelerating drug development process.
The Company has begun the research & development on
targeted drug delivery for glaucoma, arthritis and Epidermolysis
bullosa simplex. Using the advances of nanomedicine during the
past decade we are developing nanoparticle systems that have
shown great promise as targeted drug delivery vehicle.
“I believe that cannabis based medicine can deliver “intelligent drugs”
...medicines that are specific for targets that are only involved in a disease state.
—Dr. Appedino, Professor Organic Chemistry
Università del Piemonte Orientale, Italy
Leadership
Corporate Data
Head Office
350-409 Granville Street
Vancouver, BC Canada V6C 1T2
Legal Counsel
FARRIS, VAUGHAN, WILLIS & MURPHY LLP
2500-700 W Georgia St., Vancouver BC
Canada, V7Y1B3
Ticker Symbol
CSE:IN
OTCQB: IMLFF
Shares Structure
Issued & Outstanding
52,878,524 Fully Diluted
69,778,524
InMed Pharmaceuticals
350-409 Granville St.
Vancouver, BC V6C 1T2
T 604.669.7207 F 604.683.2506
CSE: IN | OTCQB: IMLFF
www.inmedpharma.com
Platform Technology
The Company is utilizing its proprietary Intelligent Cannabinoid Drug Design
Platform “IDP” to identify new bioactive compounds within the cannabis & non-
cannabis plants that interact with certain gene targets responsible for specific diseases.
It is a novel bioinformatics tool to identify individual chemical structures, which can be
targeted to develop therapies for specific diseases and conditions.
The Advantages of our “IDP”:
Generates new therapies based on scientifically proven genomics and
metabolomics both quickly and effectively.
This Network based methodologies prioritizes knowledge about disease
linkage intervals with protein identification & interactions with known disease
genes networks
Our platform allows us to uniquely prioritize certain disease genes using
known drug target genes enabling an accelerated pathway for drug
development and commercialization: ~3.5 yrs. vs. traditional 10-15 yrs.
Product Pipeline
Investment Highlights
Accelerated Development Pathway from traditional Pharmaceuticals InMed’s therapies are natural cannabinoids (reduced side effects) Our “IDP” will discover new compounds both rapidly and effectively Sdsd Sdsdd Sdsd
OUR VISION:
InMed was founded to offset and reduce the major challenges of the modern biotech/pharmaceutical industry
Craig Schneider, B.A.
President & CEO
Dr. Sazzad Hossain, Ph.D., M.Sc.,
Chief Scientific Officer
Dr. Ado Mohammed, MD, DPM, MFPM Chief Medical Officer
Dr. Tarek Mansour, Ph.D., M.Sc.,
Director
Kevin Puil, CFA
Director
Steven Tong, LLB
Director
